We are live on ! Find out more
OIM

Oracle Investment Management Portfolio holdings

AUM $168M
1-Year Est. Return 42.86%
This Fund
S&P 500
This Quarter Est. Return
+45.46%
1 Year Est. Return
+42.86%
3 Year Est. Return
+864.89%
5 Year Est. Return
+1,153.35%
10 Year Est. Return
+22,228.86%
AUM
$167M
AUM Growth
+$59.7M
Cap. Flow
+$30.3M
Cap. Flow %
18.17%
Top 10 Hldgs %
88.4%
Holding
26
New
4
Increased
6
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
PHAT icon
Phathom Pharmaceuticals
PHAT
+$7.33M
2
MYGN icon
Myriad Genetics
MYGN
+$2.02M
3
PLTR icon
Palantir
PLTR
+$844K
4
PACB icon
Pacific Biosciences
PACB
+$501K
5
BHVN icon
Biohaven
BHVN
+$187K

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$7.44M
2
WGS icon
GeneDx Holdings
WGS
+$2.03M
3
EYPT icon
EyePoint Inc
EYPT
+$1.75M
4
ARDX icon
Ardelyx
ARDX
+$702K
5
WBA
Walgreens Boots Alliance
WBA
+$333K

Sector Composition

Rank Sector Weight
1 Healthcare 72.99%
2 Consumer Discretionary 1.38%
3 Technology 0.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WGS icon
1
GeneDx Holdings
WGS
$1.84B
$44.4M 26.6%
1,045,768
-60,000
-5% -$2.03M
BHVN icon
2
Biohaven
BHVN
$2.07B
$35.2M 21.12%
705,250
+4,800
+0.7% +$187K
BHVN icon
3
CALL
Biohaven
BHVN
$2.07B
$15.1M 9.06%
302,700
+187,700
+163% +$7.3M
PHAT icon
4
Phathom Pharmaceuticals
PHAT
$930M
$13.6M 8.12%
749,487
+524,487
+233% +$7.33M
XNTK icon
5
CALL
State Street SPDR NYSE Technology ETF
XNTK
$2B
$9.88M 5.92%
+100,000
New +$18.9M
ARDX icon
6
Ardelyx
ARDX
$1.25B
$9.43M 5.65%
1,369,200
-118,931
-8% -$702K
NVAX icon
7
CALL
Novavax
NVAX
$1.21B
$6.75M 4.05%
+534,600
New +$6.9M
QDEL icon
8
QuidelOrtho
QDEL
$1.14B
$5.39M 3.23%
118,291
– –
BCRX icon
9
BioCryst Pharmaceuticals
BCRX
$2.48B
$4.07M 2.44%
535,558
– –
MYGN icon
10
Myriad Genetics
MYGN
$502M
$3.68M 2.21%
134,500
+74,500
+124% +$2.02M
PHAT icon
11
CALL
Phathom Pharmaceuticals
PHAT
$930M
$3.48M 2.09%
+192,700
New +$2.69M
ARDX icon
12
CALL
Ardelyx
ARDX
$1.25B
$2.96M 1.78%
430,200
+170,600
+66% +$1.01M
FORA
13
DELISTED
Forian
FORA
$2.93M 1.76%
1,356,107
– –
EYPT icon
14
CALL
EyePoint Inc
EYPT
$1B
$2.8M 1.68%
350,000
-88,100
-20% -$774K
CAVA icon
15
CAVA Group
CAVA
$7.57B
$2.3M 1.38%
18,600
– –
PACB icon
16
Pacific Biosciences
PACB
$432M
$1.24M 0.74%
727,877
+304,739
+72% +$501K
SWTX
17
DELISTED
SpringWorks Therapeutics
SWTX
$1.1M 0.66%
34,200
-199,000
-85% -$7.44M
PLTR icon
18
Palantir
PLTR
$296B
$1.02M 0.61%
+27,500
New +$844K
PLTR icon
19
CALL
Palantir
PLTR
$296B
$744K 0.45%
20,000
-50,000
-71% -$1.53M
BIIB icon
20
Biogen
BIIB
$30.4B
$468K 0.28%
2,412
– –
EYPT icon
21
EyePoint Inc
EYPT
$1B
$260K 0.16%
32,500
-199,357
-86% -$1.75M
BDSX icon
22
Biodesix
BDSX
$218M
$51.5K 0.03%
1,446
– –
AGEN
23
Agenus
AGEN
$275M
– –
-17,500
Closed -$293K
MYGN icon
24
CALL
Myriad Genetics
MYGN
$502M
– –
-74,500
Closed -$1.82M
SWTX
25
CALL
DELISTED
SpringWorks Therapeutics
SWTX
– –
-17,800
Closed -$671K
1
2

Similar funds

BIO
Blue Investment Opportunities Miami Beach, Florida $168M AUM 21.32% 1-Year Est. Return
OBWA
Oak Barrel Wealth Advisory Reston, Virginia $167M AUM
EECFX
EnCap Energy Capital Fund XII Houston, Texas $169M AUM
PW
Pandora Wealth Oakbrook Terrace, Illinois $165M AUM 18.5% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
AIMU
Allianz Investment Management US Minneapolis, Minnesota $160M AUM 4.75% 1-Year Est. Return
HIA
Harvest Investment Advisors Tallahassee, Florida $176M AUM
ACA
AG Campbell Advisory Baltimore, Maryland $158M AUM

Oracle Investment Management's Q3 2024 Portfolio in Review

As of Q3 2024, Oracle Investment Management held 26 positions worth $167M, up 56% from $107M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Oracle Investment Management deployed $30.3M of net new capital in Q3 2024, opening 4 new positions and adding to 6 existing holdings. Its largest new stake was Palantir: 27,500 shares worth $1.02M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 85% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $7.44M trimmed.

  • Oracle Investment Management's largest Q3 2024 buy was Palantir: 27,500 shares worth $1.02M.
  • Oracle Investment Management added most to Phathom Pharmaceuticals in Q3 2024, an estimated $7.33M increase.
  • Oracle Investment Management's biggest Q3 2024 reduction was SpringWorks Therapeutics, cutting an estimated $7.44M.
  • Oracle Investment Management fully exited Walgreens Boots Alliance in Q3 2024, selling an estimated $333K.
  • Oracle Investment Management's ten largest holdings make up 88% of its $167M portfolio in Q3 2024.
  • Oracle Investment Management opened 4 new positions and closed 4 in Q3 2024.
  • Oracle Investment Management's portfolio value rose 56% quarter-over-quarter to $167M.

Based on Oracle Investment Management's 13F filing for Q3 2024, filed 14 Nov 2024.